One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Purpose: The aim of this study is to evaluate the functional and anatomical effects of
switching from Bevacizumab to Aflibercept in patients with persistent DME resistant to
Bevacizumab.
Methods: Patients with DME refractory to Bevacizumab (1.25 mg/ 0.05 mL) were subsequently
switched to Aflibercept (2.0 mg/0.05 ml). The included patients received 5 loading doses of
intravitreal Aflibercept (2.0 mg/0.05 mL) (Eylea; Bayer, Berlin, Germany) given monthly.
After the loading dose, Aflibercept was injected every 2 months. The follow up duration was
one year.